• Title/Summary/Keyword: Eudragit

Search Result 77, Processing Time 0.026 seconds

마이크로캅셀화에 의한 조절방출제제 개발 I: 유드라짓 마이크로캅셀화에 의한 $\beta$-락탐계 항생제의 방출제어

  • Ji, Woong-Gil;Han, Gun;Jung, Yeon-Bok
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 1992.05a
    • /
    • pp.64-64
    • /
    • 1992
  • 1. Eudragit RS, RL, E, S 및 L을 이용하여 유중건조법으로 제조한 $\beta$-락탐계 항생제 (Amoxicillin, Cephalexin) 마이크로캅셀 모두가 구상 성형성과 정립성이 양호한 결과를 얻었다. 2. 분리 분산제 (aluminium tristearate)의 양을 고정시켰을 때에는 일정한 입자 분포도를 가지는 마이크로캅셀을 얻을 수 있었고, 양을 증가시켰을 때에는 입자 크기는 작아 졌으며, 용출율은 증가하였다. 3. Eudragit RS 및 S 마이크로캅셀제제로부터의 약물용출은 저조하였고, Eudragit RL 및 L 제제로부터의 약물용출은 양호하였다. 따라서 Eudragit RS/RL 마이크로캅셀제제에서는 Eudragit RL의 양을 증가시킬수록 약물의 용출율이 증가하였으며, Eudragit S/L 마이크로캅셀제제에서는 Eudragit L의 양을 증가시킬수록 약물의 용출율이 증가하였다. 약물방출 실험결과, Amoxicillin 함유Eudragit RS/RL (25/75) 마이크로캅셀, cephalxin함유 Eudragit RS/RL (75/25) 마이크로캅셀 및 Eudragit S/L (75/25) 마이크로캅셀제제는 유용한 제제로 펑가되었다. 또한 수용성 고분자인 polyethylene glycol을 혼합하어 제조하는 것에 의해 방출조절성 마이크로캅셀의 제조가 가능하였다. 유중건조법을 이용하여 본 연구방법으로 저조한 마이크로캅셀제제는 투어횟수를 줄일 수 있을 뿐만 아니라 생체에 대해 안전하고 재현성에 확보되는 유용한 제제로 판단된다. 앞으로 연구를 계속 수행하여, 특히 약물의 물리화학적 성질 및 생제내 투어 후의 생물약제학적 펑가를 엄격히 하므로써 안정성이 심히 문제시되는 다용 약물계열에 대한 조절방출성제제의 개발을 기대할 수 있다.은 해리항수의 역수이므로 해리항수가 적을수록 $\beta$ 수용체에 대한 친화력이 큰 약물이다. 시사되었으며, 이 조직에서 또한 5-$HT_2$와 5-$HT_3$ 수용체의 존재를 확인하고 각각의 기능을 분명히 했다.가 수월하게 하였고 메모리를 동적으로 관리할 수 있게 하였다. 또한 기존의 smpl에 디버깅용 함수 및 설비(facility) 제어용 함수를 추가하여 시뮬레이션 프로그램 작성을 용이하게 하였다. 예를 들면 who_server(), who_queue(), pop_Q(), push_Q(), pop_server(), push_server(), we(), wf(), printfct() 같은 함수들이다. 또한 동시에 발생되는 사건들의 순서를 조종하기 위해, 동시에 발생할 수 있는 각각의 사건에 우선순위를 두어 이 우선 순위에 의하여 사건 리스트(event list)에서 자동적으로 사건들의 순서가 결정되도록 확장하였으며, 설비 제어방식에 있어서도 FIFO, LIFO, 우선 순위 방식등을 선택할 수 있도록 확장하였다. SIMPLE는 자료구조 및 프로그램이 공개되어 있으므로 프로그래머가 원하는 기능을 쉽게 추가할 수 있는 장점도 있다. 아울러 SMPLE에서 새로이 추가된 자료구조와 함수 및 설비제어 방식등을 활용하여 실제 중형급 시스템에 대한 시뮬레이션 구현과 시스템 분석의 예를 보인다._3$", chain segment, with the activation energy of carriers from the shallow trap with 0.4[eV], in he amorphous regions.의 증발산율은 우기의 기상자료를 이용하여 구한 결과 0.05 - 0.10 mm/hr 의 범위로서 이로 인한 강우손실량은 큰 의미가 없음

  • PDF

In Vitro Dissolution of Felodipine from Extended-Release Pellets (펠로디핀 방출연장형 펠렛의 용출 특성 평가)

  • Park, Jeong-Sook;Nam, Kyung-Wan;Shin, Kwang-Hyun;Park, Jong-Bum;Kim, Min-Soo;Hwang, Sung-Joo
    • Journal of Pharmaceutical Investigation
    • /
    • v.37 no.3
    • /
    • pp.193-196
    • /
    • 2007
  • This study aimed to evaluate and develop $Eudragit^{(R)}$-coated pellets based on the dissolution using the paddle method. As coating materials, two types of $Eudragit^{(R)}$ were applied to obtain either sustained release form or fast released form. The dissolution test was carried out in phosphate buffer solution (pH 6.5) at $37^{\circ}C$, 100 rpm. In order to develop a sustained release preparation containing felodipine, a comparative dissolution study was done using commercial product as a control. The dissolution at 30 min of felodipine from $Eudragit^{(R)}$ RS or RL-coated pellets were 0.96% and 99.65, respectively. The weight ratio of $Eudragit^{(R)}$ RL pellets to RS pellets altered the dissolution rate, but did not optimize the dissolution rate. However, the sustained dissolution of felodipine from pellets was optimized by varying the coating ratios of $Eudragit^{(R)}$ RS. It is suggested that the coating ratio of pellets is the main factor which controls dissolution rate. Taken together, $Eudragit^{(R)}$ RS 30D-coated pellets showed the most comparable dissolution rate pattern to commercial product, $Splendil^{(R)}$. This sustained release pellets for oral delivery system of felodipine was simply manufactured, and drug release behavior was highly reproducible.

Microencapsulation of Nalidixic Acid Using Eudragit RL (Nalidixic Acid의 Eudragit RL Microencapsulation에 관한 연구)

  • Ku, Young-Soon;Choi, Kyung-Joo
    • YAKHAK HOEJI
    • /
    • v.34 no.3
    • /
    • pp.199-205
    • /
    • 1990
  • Microencapsulation of nalidixic acid using Eudragit RL, a methacrylic acid copolymer was investigated. Microcapsules were prepared by dispersing the drug solution in liquid paraffing using aluminium tristearate as dispersing agent. The preparation of the microcapsules showed high reprodulibility in particle size, shape and the drug content. The dissolution rates of Nalidixic acid from the these microcapsules considerably decreased as compared with that from Nalidixic acid powder and Nalidixic acid-Eudragit RL solid dispersions. The release of Nalidixic acid increased with increasing percentage of aluminium tristearate added to the microcapsules.

  • PDF

Development and Characterization of Membrane for Local Delivery of Cephalexin

  • Shin, Sang-Chul;Oh, In-Joon;Cho, Seong-Jin
    • Archives of Pharmacal Research
    • /
    • v.19 no.1
    • /
    • pp.1-5
    • /
    • 1996
  • Laminated films composed of drug-containing reservoir layer and drug-free membrane were prepared. Zero-order drug release with lag time was achieved by laminating drug-free film onto the reservoir layer, while burst effect was observed on cast-on film. The rate controlling membrane was either attached to or cast directly into the reservoir. The release rate was independent on the reservoir composition but dependent on the composition of rate-controlling membrane. In growth inhibitory test of cephalexin from Eudragit RS film to Streptococcus Mutans, the disk even after release test for 72 hours showed more bacterial growth inhibition than that of control. Permeation of drug through rat skin was proportional to the HPC fraction in the film. We could control the release of cephalexin from the film by changing the fraction of Eudragit RS, HPC and DEP content. Consequently, Eudragit RS/HPC film was found to be very effective system for local delivery of drugs.

  • PDF

Preparation of Eudragit coated solid lipid nanoparticles (SLN) for hydrophilic drug delivery

  • Han, Sung-Chul;Yoon, Hee-Sun;Lee, Ki-Young;Kim, Yeon-Zu;Kim, Dong-Woon
    • 한국생물공학회:학술대회논문집
    • /
    • 2003.10a
    • /
    • pp.655-659
    • /
    • 2003
  • Solid lipid nanoparticle (SLN) system has been attracted increasing attention during last few years as a potential drug delivery carrier However, the SLN have disadvantage of low encapsulation efficiency for hydrophilic drug. In this study, for increase it's encapsulation efficiency, we prepared the $Eudragit^{\circledR}$ L100-55 (eudragit) coated SLN(E-SLN) based on solvent evaporation method and melt dispersion technique, and analyzed their physicochemical properties in terms of particle size, morphology, and encapsulation efficiency. As a result, they have a ${\pm}150$ nm particle size, spherical shape, and $10^{\sim}25$ % loading efficiency. SLN consists of coconut oil as core material, ascorbic acid and okyong-san as hydrophilic drug.

  • PDF

Controlled Release Properties of Ketoprofen from Methacrylate Polymer Gels (메타크릴레이트 폴리머로 제조한 겔 제제로부터 케토프로펜의 제어 방출특성)

  • Han, Kun;Park, Jeong-Sook;Kim, Nak-Seo;Chung, Youn-Bok;Cha, Cheol-Hee
    • Journal of Pharmaceutical Investigation
    • /
    • v.21 no.1
    • /
    • pp.1-10
    • /
    • 1991
  • Hydrogels containing ketoprofen were prepared by adding NaOH or $Ca(OH)_2$ solution to Eudragit L, S and Eudispert hv at various concentration. And xerogels were prepared by drying hydrogels. On the other hand, organogels containing ketoprofen were prepared by mixing Eudragit L or S and propylene glycol. Effects of polymer content and base on drug release were investigated using KP V dissolution method. The release rate of ketoprofen from Eudragit L & S hydrogel decreased with increasing in polymer content. And the drug release rate from cal. hydroxide based gels were more decreased than that from sod. hydroxide based gels. At pH 7.2 dissolution medium, e release of ketoprofen from Edispert hv hydrogel followed apparent zero order kinetics. The release of ketoprofen from xerogel involved in simultaneous absorption of water and desorption of ketoprofen via a pH-dependant swelling controlled mechanism. The release of ketoprofen from Eudragit S organogels followed apparent zero order kinetics, providing strong evidence for a surface erosion mechanism.

  • PDF

Immobilization of the Antarctic Bacillus sp. LX-1 α-Galactosidase on Eudragit L-100 for the Production of a Functional Feed Additive

  • Lee, Jaekoo;Park, Inkyung;Cho, Jaiesoon
    • Asian-Australasian Journal of Animal Sciences
    • /
    • v.26 no.4
    • /
    • pp.552-557
    • /
    • 2013
  • Partially purified ${\alpha}$-galactosidase from Bacillus sp. LX-1 was non-covalently immobilized on a reversibly soluble-insoluble polymer, Eudragit L-100, and an immobilization efficiency of 0.93 was obtained. The optimum pH of the free and immobilized enzyme was 6.5 to 7.0 and 7.0, respectively, while there was no change in optimum temperature between the free and immobilized ${\alpha}$-galactosidase. The immobilized ${\alpha}$-galactosidase was reutilized six times without significant loss in activity. The immobilized enzyme showed good storage stability at $37^{\circ}C$, retaining about 50% of its initial activity even after 18 d at this temperature, while the free enzyme was completely inactivated. The immobilization of ${\alpha}$-galactosidase from Bacillus sp. LX-1 on Eudragit L-100 may be a promising strategy for removal of ${\alpha}$-galacto-oligosaccharides such as raffinose and stachyose from soybean meal and other legume in feed industry.

Preparation and Evaluation of Sustained Release Aspirin Microcapsules Using Eudragit $RS^{\circledR}$ Polymer (Eudragit $RS^{\circledR}$를 이용한 지속 방출형 아스피린 마이크로캅셀의 제조 및 평가)

  • Chun, In-Koo;Shin, Dong-Won
    • YAKHAK HOEJI
    • /
    • v.32 no.1
    • /
    • pp.26-39
    • /
    • 1988
  • Eudragit $RS^{\circledR}$ polymer was used as a wall material for the microencapsulation of aspirin by a phase separation method from chloroform-cyclohexane system with 5% polyisobutylene (PIB) in cyclohexane, and microcapsules obtained were evaluated by particle size analysis, scanning electron microscopy (SEM), drug release and drug stability test. With PIB as a coacervation inducing agent, smooth and tight microcapsules with less aggregation were obtained. Below 1 : 0.3 core-wall ratio, it was possible to coat individual particle. Variation of production conditions showed that increasing the proportion of wall material, particle size and wall thickness of microcapsules and the concentration of paraffin wax in cyclohexane as a sealant sustained drug release rates effectively. SEM confirmed that larger microcapsules after drug release did not rupture into smaller particles but contained a few small pores on the surface. Aspirin release from Eudragit $RS^{\circledR}$ coated microcapsules was independent of the pH of medium, and the mechanism of drug release from non-sealed and sealed microcapsules appeared to fit Higuchi matrix model kinetics. Aspirin in the mixture of aspirin microcapsules and sodium bicarbonate was by far more stable than that in the mixture of pure aspirin and sodium bicarbonate.

  • PDF

Improved Dissolution of Solid Dispersed Atorvastatin Using Spray-Dryer (분무건조기를 이용한 아토르바스타틴 고체분산체의 용출율 개선)

  • Lee, Jun-Hee;Kim, Dae-Sung;Kim, Won;Park, Jong-Hak;Ahn, Sik-Il;Kim, Yun-Tae;Rhee, John-M.;Khang, Gil-Son
    • Journal of Pharmaceutical Investigation
    • /
    • v.38 no.4
    • /
    • pp.249-254
    • /
    • 2008
  • Solid dispersions of poorly water-soluble drug, atorvastatin, were prepared with Eudragit L100 to improve the solubility by spray dryer. To investigate the correlation between physicochemical properties and dissolution rate of solid dispersions, the samples were characterized by scanning electron microscopy (SEM), differential scanning calorimeter (DSC) and fourier transform infrared spectroscopy (FT-IR). SEM and DSC were found that atorvastatin is amorphous in the Eudragit L100 solid dispersion. FT-IR was used to analyze the salt formation by interaction between atorvastatin and Eudragit L100. The dissolution rate of solid dispersed atorvastatin was markedly increased compared to drug powder in stimulated intestinal juice (pH 6.8). Thus, the solid dispersed atorvastatin using the spray drying method with Eudragit L100 may be effective for the bioavailability.

Formulation and Preparation of Sustained Release Pellet for Alfuzosin HCI Using Fluid-bed coater (유동층 코팅기를 이용한 염산알푸조신의 서방형 과립 설계 및 제조)

  • Na, Jin-Sang;Yoon, Yang-No;Seo, Hui;Jeong, Sang-Young;Park, Eun-Seok;Hwan, Sung-Joo;Shin, Byung-Cheol;Kim, Sung-Hoon;Cho, Sun-Hang
    • Journal of Pharmaceutical Investigation
    • /
    • v.38 no.6
    • /
    • pp.387-392
    • /
    • 2008
  • Alfuzosin, an Alphal-adrenoceptor antagonist is used for the treatment of patients with voiding and in a lesser extent storage lower urinary tract symptoms (LUTS) associated to benign prostatic hyperplasia (BPH). The objective of this study was to formulate sustained release alfuzosin HCl granules and assess their formulation variables. The $Eudragit^{(R)}$ as a polymer, sustained release membrane, and dibutyl sebacate (DBS) as a plasticizer were used. Multi-coated alfuzosin HCl delivery systems composed of sugar sphere, various excipients, $Eudragit^{(R)}$ and HPMC (hydroxy propyl methyl cellulose), Cellulose Acetate were prepared by fluid-bed coater. Membrane layer were used $Eudragit^{(R)}$ RS PO and NE 30D. And the alfuzosin HCl coated beads were coated immediate release drug layer for initial burst. Its dissolution test was carried out compared to conventional products ($XATRAL^{(R)}$ XL). The release rate of drug from coated beads was higher than that from $XATRAL^{(R)}$ XL in pH 6.8.